04671cam a2200697 a 4500 ocn769289644 OCoLC 20171115133904.0 m o d cr cnu---unuuu 111222s2012 nju ob 001 0 eng 2011052987 9781118309407 (epub) 1118309405 (epub) 9781118309384 (epdf) 1118309383 (epdf) 9781118309391 (emobi) 1118309391 (emobi) 9781118309421 (electronic bk.) 1118309421 (electronic bk.) 1280699310 9781280699313 0470322829 (cloth) 9780470322826 (cloth) 9780470322826 (cloth) AU@ 000048329675 DKDLA 820120-katalog:000599860 NZ1 14693634 DEBBG BV043393917 (OCoLC)769289644 (OCoLC)795894798 (OCoLC)798698963 (OCoLC)808669946 (OCoLC)817089457 (OCoLC)961501567 (OCoLC)962591718 (OCoLC)966253987 10.1002/9781118309421 Wiley InterScience http://www3.interscience.wiley.com DLC eng pn DLC EBLCP IDEBK N$T DG1 YDXCP E7B STF COO UBY NLGGC OCLCF OCLCQ OCLCO OCLCQ OCLCO OCLCQ OCLCO DEBBG AZK OCLCQ LOA OCLCO OCLCA pcc MAIN RC514 WM 203 PSY 022050 bisacsh 616.89/8061 23 Targets and emerging therapies for schizophrenia / edited by Jeffrey S. Albert, Michael W. Wood. [electronic resource] Hoboken, New Jersey : John Wiley & Sons, ©2012. 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier data file rda Bibliography Includes bibliographical references and index. Dopaminergic hypothesis of schizophrenia : a historical perspective / Aurelija Jucaite and Svante Nyberg -- Dopamine D2/D3 partial agonists as antipsychotics / Philip G. Strange -- D1/D5 dopamine agonists as pharmacotherapy for schizophrenia / Kevin N. Boyd and Richard B. Mailman -- PDE inhibitors as a novel therapeutic approach for schizophrenia / Judith A. Siuciak and William J. Pitts -- Glutamatergic synaptic dysregulation in schizophrenia / Joseph T. Coyle, Alo Basu, and Michael Benneyworth -- Metabotropic glutamate 2/3 receptor agonists and positive allosteric modulators of metabotropic glutamate receptor 2 as novel agents for the treatment of schizophrenia / Gerard J. Marek [and others] -- AMPA receptor positive modulators / John A. Morrow, John K.F. Maclean, and Craig Jamieson -- Progress in the exploration and development of GlyT1 inhibitors for schizophrenia / Jeffrey S. Albert and Michael W. Wood -- Combined dopamine D2 and 5-hydroxytryptamine (5-HT)1a receptor strategies for the treatment of schizophrenia, a pharmacological and chemical perspective / Andrew C. Mccreary, Roelof W. Feenstra, and Caitlin A. Jones -- 5-HT2C and 5-HT6 receptor targeted emerging approaches in schizophrenia / Sharon Rosenzweig-Lipson [and others] -- The cholinergic hypothesis : an introduction to the hypothesis and a short history / Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic -- À7 nicotinic acetylcholine receptors in the treatment of schizophrenia / Mihály Hajós, and Bruce N. Rogers -- Muscarinic acetylcholine receptors as novel targets for the development of therapeutics for schizophrenia / Christian C. Felder [and others] -- Will modulation of neuropeptide receptors produce the next generation of antipsychotic drugs? : a focus on the neurokinin and neurotensin systems / Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson -- GABA and schizophrenia / John H. Kehne and George D. Maynard. Print version record and CIP data provided by publisher. Schizophrenia Treatment. Schizophrenia drug therapy. PSYCHOLOGY Psychopathology Schizophrenia. bisacsh Schizophrenia Treatment. fast (OCoLC)fst01106780 Electronic books. Electronic books. local Albert, Jeffrey S. Wood, Michael W. (Michael William), 1961- Print version: Targets and emerging therapies for schizophrenia. Hoboken, N.J. : John Wiley & Sons, ©2012 9780470322826 (DLC) 2011051091 http://onlinelibrary.wiley.com/book/10.1002/9781118309421 Wiley Online Library ddc BK 205474 205474